Jane Street
XERS icon

Jane Street’s Xeris Biopharma Holdings XERS Stock Holding History

Jane Street’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Sell
61,915
-663,701
-91% -$4.24M ﹤0.01% 8077
2026
Q1 		$4.21M Buy
725,616
+547,794
+308% +$3.63M ﹤0.01% 3758
2025
Q4 		$1.4M Sell
177,822
-735,936
-81% -$5.79M ﹤0.01% 5459
2025
Q3 		$7.44M Buy
913,758
+882,593
+2,832% +$5.86M ﹤0.01% 2827
2025
Q2 		$146K Sell
31,165
-789,057
-96% -$3.62M ﹤0.01% 8773
2025
Q1 		$4.5M Buy
820,222
+513,977
+168% +$2.07M ﹤0.01% 3088
2024
Q4 		$1.04M Sell
306,245
-12,515
-4% -$40.3K ﹤0.01% 5311
2024
Q3 		$908K Sell
318,760
-28,832
-8% -$74K ﹤0.01% 6079
2024
Q2 		$782K Buy
347,592
+117,634
+51% +$237K ﹤0.01% 6248
2024
Q1 		$508K Buy
229,958
+6,374
+3% +$16.5K ﹤0.01% 6631
2023
Q4 		$525K Buy
223,584
+79,980
+56% +$148K ﹤0.01% 6671
2023
Q3 		$267K Buy
143,604
+17,189
+14% +$39.4K ﹤0.01% 7238
2023
Q2 		$331K Sell
126,415
-9,407
-7% -$23.9K ﹤0.01% 6969
2023
Q1 		$221K Sell
135,822
-45,740
-25% -$57.3K ﹤0.01% 7699
2022
Q4 		$241K Buy
181,562
+63,964
+54% +$90.3K ﹤0.01% 7377
2022
Q3 		$183K Sell
117,598
-148,698
-56% -$246K ﹤0.01% 8258
2022
Q2 		$410K Sell
266,296
-196,583
-42% -$415K ﹤0.01% 7089
2022
Q1 		$1.19M Buy
462,879
+349,469
+308% +$854K ﹤0.01% 5779
2021
Q4 		$332K Buy
113,410
+97,476
+612% +$211K ﹤0.01% 7988
2021
Q3 		$39K Sell
15,934
-14,660
-48% -$42.6K ﹤0.01% 9623
2021
Q2 		$125K Sell
30,594
-20,325
-40% -$77.6K ﹤0.01% 9160
2021
Q1 		$230K Buy
50,919
+25,495
+100% +$138K ﹤0.01% 8083
2020
Q4 		$125K Buy
+25,424
New +$127K ﹤0.01% 7139

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jane Street's XERS Position: Q2 2026 in Review

Jane Street reduced its Xeris Biopharma Holdings (XERS) stake by 91% in Q2 2026, selling an estimated $4.24M and leaving 61,915 shares worth $490K. The position accounts for ﹤0.01% of the portfolio, ranked #8077.

Jane Street first reported a position in XERS in Q4 2020 and has held it in 23 quarters since. The position peaked at $7.44M in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Jane Street held 61,915 shares of Xeris Biopharma Holdings worth $490K as of Q2 2026.
  • Jane Street sold 663,701 Xeris Biopharma Holdings shares in Q2 2026, an estimated $4.24M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8077 holding.
  • Jane Street first reported a position in Xeris Biopharma Holdings in Q4 2020 and has held it in 23 quarters since.
  • Jane Street's Xeris Biopharma Holdings position peaked at $7.44M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.